Literature DB >> 33579389

Contribution of rare homozygous and compound heterozygous VPS13C missense mutations to dementia with Lewy bodies and Parkinson's disease.

Stefanie Smolders1,2,3, Stéphanie Philtjens1,2,3, David Crosiers1,2,3,4, Anne Sieben1,2,5, Elisabeth Hens1,2,3,4,6, Bavo Heeman1,2,3, Sara Van Mossevelde1,2,4,6, Philippe Pals2,4, Bob Asselbergh1,2,3, Roberto Dos Santos Dias7, Yannick Vermeiren2,3, Rik Vandenberghe8,9, Sebastiaan Engelborghs2,3,10, Peter Paul De Deyn2,3,6, Jean-Jacques Martin2, Patrick Cras2,3,4, Wim Annaert7, Christine Van Broeckhoven11,12,13,14.   

Abstract

Dementia with Lewy bodies (DLB) and Parkinson's disease (PD) are clinically, pathologically and etiologically disorders embedded in the Lewy body disease (LBD) continuum, characterized by neuronal α-synuclein pathology. Rare homozygous and compound heterozygous premature termination codon (PTC) mutations in the Vacuolar Protein Sorting 13 homolog C gene (VPS13C) are associated with early-onset recessive PD. We observed in two siblings with early-onset age (< 45) and autopsy confirmed DLB, compound heterozygous missense mutations in VPS13C, p.Trp395Cys and p.Ala444Pro, inherited from their healthy parents in a recessive manner. In lymphoblast cells of the index patient, the missense mutations reduced VPS13C expression by 90% (p = 0.0002). Subsequent, we performed targeted resequencing of VPS13C in 844 LBD patients and 664 control persons. Using the optimized sequence kernel association test, we obtained a significant association (p = 0.0233) of rare VPS13C genetic variants (minor allele frequency ≤ 1%) with LBD. Among the LBD patients, we identified one patient with homozygous missense mutations and three with compound heterozygous missense mutations in trans position, indicative for recessive inheritance. In four patients with compound heterozygous mutations, we were unable to determine trans position. The frequency of LBD patient carriers of proven recessive compound heterozygous missense mutations is 0.59% (5/844). In autopsy brain tissue of two unrelated LBD patients, the recessive compound heterozygous missense mutations reduced VPS13C expression. Overexpressing of wild type or mutant VPS13C in HeLa or SH-SY5Y cells, demonstrated that the mutations p.Trp395Cys or p.Ala444Pro, abolish the endosomal/lysosomal localization of VPS13C. Overall, our data indicate that rare missense mutations in VPS13C are associated with LBD and recessive compound heterozygous missense mutations might have variable effects on the expression and functioning of VPS13C. We conclude that comparable to the recessive inherited PTC mutations in VPS13C, combinations of rare recessive compound heterozygous missense mutations reduce VPS13C expression and contribute to increased risk of LBD.

Entities:  

Keywords:  DLB; Dementia with lewy bodies; Lewy body disease; Loss-of-function; Missense mutations; PD; Parkinson’s disease; Recessive inheritance; VPS13C; Vacuolar protein sorting 13 homolog C

Year:  2021        PMID: 33579389      PMCID: PMC7881566          DOI: 10.1186/s40478-021-01121-w

Source DB:  PubMed          Journal:  Acta Neuropathol Commun        ISSN: 2051-5960            Impact factor:   7.801


  43 in total

1.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease.

Authors:  S S Mirra; A Heyman; D McKeel; S M Sumi; B J Crain; L M Brownlee; F S Vogel; J P Hughes; G van Belle; L Berg
Journal:  Neurology       Date:  1991-04       Impact factor: 9.910

2.  The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment.

Authors:  Ziad S Nasreddine; Natalie A Phillips; Valérie Bédirian; Simon Charbonneau; Victor Whitehead; Isabelle Collin; Jeffrey L Cummings; Howard Chertkow
Journal:  J Am Geriatr Soc       Date:  2005-04       Impact factor: 5.562

Review 3.  Clinical and neuropathological differences between Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies - current issues and future directions.

Authors:  Lauren Walker; Leonidas Stefanis; Johannes Attems
Journal:  J Neurochem       Date:  2019-04-23       Impact factor: 5.372

Review 4.  A systematic review of prevalence studies of dementia in Parkinson's disease.

Authors:  Dag Aarsland; Julia Zaccai; Carol Brayne
Journal:  Mov Disord       Date:  2005-10       Impact factor: 10.338

5.  Familial dementia with Lewy bodies with an atypical clinical presentation.

Authors:  Lauren T Bonner; Debby W Tsuang; Monique M Cherrier; Charisma J Eugenio; Q Du Jennifer; Ellen J Steinbart; Pornprot Limprasert; Albert R La Spada; Benjamin Seltzer; Thomas D Bird; James B Leverenz
Journal:  J Geriatr Psychiatry Neurol       Date:  2003-03       Impact factor: 2.680

Review 6.  The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies.

Authors:  S A Vann Jones; J T O'Brien
Journal:  Psychol Med       Date:  2013-03-25       Impact factor: 7.723

7.  Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies.

Authors:  Mike A Nalls; Cornelis Blauwendraat; Costanza L Vallerga; Karl Heilbron; Sara Bandres-Ciga; Diana Chang; Manuela Tan; Demis A Kia; Alastair J Noyce; Angli Xue; Jose Bras; Emily Young; Rainer von Coelln; Javier Simón-Sánchez; Claudia Schulte; Manu Sharma; Lynne Krohn; Lasse Pihlstrøm; Ari Siitonen; Hirotaka Iwaki; Hampton Leonard; Faraz Faghri; J Raphael Gibbs; Dena G Hernandez; Sonja W Scholz; Juan A Botia; Maria Martinez; Jean-Christophe Corvol; Suzanne Lesage; Joseph Jankovic; Lisa M Shulman; Margaret Sutherland; Pentti Tienari; Kari Majamaa; Mathias Toft; Ole A Andreassen; Tushar Bangale; Alexis Brice; Jian Yang; Ziv Gan-Or; Thomas Gasser; Peter Heutink; Joshua M Shulman; Nicholas W Wood; David A Hinds; John A Hardy; Huw R Morris; Jacob Gratten; Peter M Visscher; Robert R Graham; Andrew B Singleton
Journal:  Lancet Neurol       Date:  2019-12       Impact factor: 44.182

Review 8.  Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium.

Authors:  I G McKeith; D W Dickson; J Lowe; M Emre; J T O'Brien; H Feldman; J Cummings; J E Duda; C Lippa; E K Perry; D Aarsland; H Arai; C G Ballard; B Boeve; D J Burn; D Costa; T Del Ser; B Dubois; D Galasko; S Gauthier; C G Goetz; E Gomez-Tortosa; G Halliday; L A Hansen; J Hardy; T Iwatsubo; R N Kalaria; D Kaufer; R A Kenny; A Korczyn; K Kosaka; V M Y Lee; A Lees; I Litvan; E Londos; O L Lopez; S Minoshima; Y Mizuno; J A Molina; E B Mukaetova-Ladinska; F Pasquier; R H Perry; J B Schulz; J Q Trojanowski; M Yamada
Journal:  Neurology       Date:  2005-10-19       Impact factor: 9.910

9.  A general framework for estimating the relative pathogenicity of human genetic variants.

Authors:  Martin Kircher; Daniela M Witten; Preti Jain; Brian J O'Roak; Gregory M Cooper; Jay Shendure
Journal:  Nat Genet       Date:  2014-02-02       Impact factor: 38.330

10.  Analysis of common and rare VPS13C variants in late-onset Parkinson disease.

Authors:  Uladzislau Rudakou; Jennifer A Ruskey; Lynne Krohn; Sandra B Laurent; Dan Spiegelman; Lior Greenbaum; Gilad Yahalom; Alex Desautels; Jacques Y Montplaisir; Stanley Fahn; Cheryl H Waters; Oren Levy; Caitlin M Kehoe; Sushma Narayan; Yves Dauvilliers; Nicolas Dupré; Sharon Hassin-Baer; Roy N Alcalay; Guy A Rouleau; Edward A Fon; Ziv Gan-Or
Journal:  Neurol Genet       Date:  2020-01-09
View more
  8 in total

Review 1.  XK-Associated McLeod Syndrome: Nonhematological Manifestations and Relation to VPS13A Disease.

Authors:  Kevin Peikert; Andreas Hermann; Adrian Danek
Journal:  Transfus Med Hemother       Date:  2022-01-25       Impact factor: 3.747

2.  Inter-organellar Communication in Parkinson's and Alzheimer's Disease: Looking Beyond Endoplasmic Reticulum-Mitochondria Contact Sites.

Authors:  Stephanie Vrijsen; Céline Vrancx; Mara Del Vecchio; Johannes V Swinnen; Patrizia Agostinis; Joris Winderickx; Peter Vangheluwe; Wim Annaert
Journal:  Front Neurosci       Date:  2022-06-21       Impact factor: 5.152

3.  ER-lysosome lipid transfer protein VPS13C/PARK23 prevents aberrant mtDNA-dependent STING signaling.

Authors:  William Hancock-Cerutti; Zheng Wu; Peng Xu; Narayana Yadavalli; Marianna Leonzino; Arun Kumar Tharkeshwar; Shawn M Ferguson; Gerald S Shadel; Pietro De Camilli
Journal:  J Cell Biol       Date:  2022-06-03       Impact factor: 8.077

Review 4.  Yeast as a Model to Find New Drugs and Drug Targets for VPS13-Dependent Neurodegenerative Diseases.

Authors:  Joanna Kaminska; Piotr Soczewka; Weronika Rzepnikowska; Teresa Zoladek
Journal:  Int J Mol Sci       Date:  2022-05-04       Impact factor: 6.208

Review 5.  Crosstalk of organelles in Parkinson's disease - MiT family transcription factors as central players in signaling pathways connecting mitochondria and lysosomes.

Authors:  Martin Lang; Peter P Pramstaller; Irene Pichler
Journal:  Mol Neurodegener       Date:  2022-07-16       Impact factor: 18.879

6.  Genetic Dissection of Vps13 Regulation in Yeast Using Disease Mutations from Human Orthologs.

Authors:  Jae-Sook Park; Nancy M Hollingsworth; Aaron M Neiman
Journal:  Int J Mol Sci       Date:  2021-06-08       Impact factor: 6.208

Review 7.  PARK Genes Link Mitochondrial Dysfunction and Alpha-Synuclein Pathology in Sporadic Parkinson's Disease.

Authors:  Wen Li; YuHong Fu; Glenda M Halliday; Carolyn M Sue
Journal:  Front Cell Dev Biol       Date:  2021-07-06

8.  Investigating the Endo-Lysosomal System in Major Neurocognitive Disorders Due to Alzheimer's Disease, Frontotemporal Lobar Degeneration and Lewy Body Disease: Evidence for SORL1 as a Cross-Disease Gene.

Authors:  Luisa Benussi; Antonio Longobardi; Cemile Kocoglu; Matteo Carrara; Sonia Bellini; Clarissa Ferrari; Roland Nicsanu; Claudia Saraceno; Cristian Bonvicini; Silvia Fostinelli; Roberta Zanardini; Marcella Catania; Matthieu Moisse; Philip Van Damme; Giuseppe Di Fede; Giuliano Binetti; Christine Van Broeckhoven; Julie van der Zee; Roberta Ghidoni
Journal:  Int J Mol Sci       Date:  2021-12-20       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.